摘要
免疫治疗能激发特异性抗肿瘤免疫,被认为是肝癌最有前景的治疗方法。激活特异性抗肿瘤免疫治疗策略主要针对肿瘤相关抗原或在感染肝炎的肝癌患者中针对病毒抗原,以及全肿瘤细胞或肿瘤溶解物激发针对未明确的或突变的肿瘤抗原的免疫反应。细胞因子、自体肿瘤疫苗、效应细胞过继治疗以及树突状细胞疫苗等治疗策略的安全性已经临床实验验证,并在临床治疗中显示出较好效果。
Immunotherapy can active specific immune response against tumor,which has been regarded to be prospective for treatment of hepatocellular carcinoma （ HCC ）. Activation of an HCC-specific response can be achieved by strategies targeting tumor-associated antigens or viral antigens in those patients infected with hepatitis B or C. Uncharacterized and mutated antigens can also be targeted with whole tumor cell or tumor lysate-based immunization strategies. Strategies which have been tested in human clinical trials include cytokine injections, autologous tumor-based immunotherapy, adoptive transfer of lymphocytes as well as autol- ogous tumor-pulsed dendritic ceils （ DC ）. These trials, testing the safety of novel immune-based interventions in HCC subjects,have resulted in immunological responses and some have impacted recurrence and survival of HCC subjects.
出处
《医学综述》
2008年第17期2614-2617,共4页
Medical Recapitulate
基金
北京市自然科学基金(7082084)
关键词
肝癌
肿瘤抗原
树突状细胞
过继免疫
细胞因子
Hepatocellular carcinoma
Tumor antigen
Dendritic cell
Adoptive transfer
Cytokine
